使用恩夫韦肽和替拉那韦联合进行孕产妇治疗预防多药耐药HIV-1的母婴传播 - Suppr

Suppr

超能文献

Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir.

作者信息

Wensing Annemarie Mj, Boucher Charles Ab, van Kasteren Marjo, van Dijken Pieter J, Geelen Sybil P, Juttmann Job R

出版信息

AIDS. 2006 Jun 26;20(10):1465-7. doi: 10.1097/01.aids.0000233587.94961.4f.

DOI:10.1097/01.aids.0000233587.94961.4f

PMID:16791028

Abstract

摘要

相似文献

Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir.

AIDS. 2006 Jun 26;20(10):1465-7. doi: 10.1097/01.aids.0000233587.94961.4f.

Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancy.

Int J STD AIDS. 2008 Sep;19(9):644-5. doi: 10.1258/ijsa.2008.008100.

Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta.

AIDS. 2006 Jan 9;20(2):297-9. doi: 10.1097/01.aids.0000200535.02232.1b.

A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide.

Eur J Med Res. 2009 Jan 28;14(1):44-6.

Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen.

AIDS. 2005 Jun 10;19(9):989-90. doi: 10.1097/01.aids.0000171417.84162.af.

Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.

AIDS. 2006 Oct 3;20(15):1977-9. doi: 10.1097/01.aids.0000247121.19951.fa.

Efficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation.

Infez Med. 2009 Dec;17(4):228-35.

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.

AIDS. 2007 Sep 12;21(14):1977-80. doi: 10.1097/QAD.0b013e3282ef8600.

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.

Lancet. 2006 Aug 5;368(9534):466-75. doi: 10.1016/S0140-6736(06)69154-X.

Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice.

Int J STD AIDS. 2007 Sep;18(9):630-2. doi: 10.1258/095646207781568493.

引用本文的文献

HIV protease inhibitors in pregnancy : pharmacology and clinical use.

Drugs. 2013 Mar;73(3):229-47. doi: 10.1007/s40265-013-0017-3.

Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

HIV AIDS (Auckl). 2009;1:41-53. doi: 10.2147/hiv.s6326. Epub 2009 Dec 8.

German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

Eur J Med Res. 2009 Nov 3;14(11):461-79. doi: 10.1186/2047-783x-14-11-461.

Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.

Retrovirology. 2008 Mar 31;5:31. doi: 10.1186/1742-4690-5-31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验